Insider · CIK 0002005474
Robert E Claypoole
Files at BVS (Bioventus Inc.). First filing Jan 14, 2025, latest Jan 14, 2025.
Robert E Claypoole files SEC Form 4 as CEO, president and director at BVS (Bioventus Inc.). Since Jan 14, 2025, Robert E Claypoole has reported 0 open-market buys worth $0 and 1 open-market sell worth $262k, the latest filed on Jan 14, 2025.
A track record needs three past buys with six months of prices behind them; Robert E Claypoole has 0, so none is measured yet.
The newest scored trade: sold $262k of BVS on Jan 13, 2025, filed Jan 14, 2025, scored 28 (weak), under a 10b5-1 plan.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
BVS: Bioventus Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Jan 13, 2025 | BVS Bioventus Inc. | 33,000 0.05% of outstanding | $315k | Jan 13, 2025 | none |
Transactions
Every row this insider has filed, 13 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Mar 13, 2026 | BVS Bioventus Inc. | MOption exercise Class A Common Stock | +33,500 | $0.00 | $0 | 150,497 | Mar 17, 2026 |
| Mar 13, 2026 | BVS Bioventus Inc. | FTax withholding Class A Common Stock | -14,553 | $8.62 | $125k | 135,944 | Mar 17, 2026 |
| Mar 14, 2025 | BVS Bioventus Inc. | AGrant or award Restricted Stock Unitsderivative | +134,000 | $0.00 | $0 | 134,000 | Mar 17, 2026 |
| Mar 14, 2025 | BVS Bioventus Inc. | AGrant or award Stock Option (Right to Buy)derivative | +153,000 | $0.00 | $0 | 153,000 | Mar 17, 2026 |
| Mar 13, 2026 | BVS Bioventus Inc. | AGrant or award Restricted Stock Unitsderivative | +278,000 | $0.00 | $0 | 278,000 | Mar 17, 2026 |
| Mar 13, 2026 | BVS Bioventus Inc. | AGrant or award Stock Option (Right to Buy)derivative | +309,000 | $0.00 | $0 | 309,000 | Mar 17, 2026 |
| Mar 13, 2026 | BVS Bioventus Inc. | MOption exercise Restricted Stock Unitsderivative | -33,500 | $0.00 | $0 | 100,500 | Mar 17, 2026 |
| Jan 9, 2026 | BVS Bioventus Inc. | MOption exercise Class A Common Stock | +93,750 | $0.00 | $0 | 158,714 | Jan 13, 2026 |
| Jan 9, 2026 | BVS Bioventus Inc. | FTax withholding Class A Common Stock | -41,717 | $8.03 | $335k | 116,997 | Jan 13, 2026 |
| Jan 9, 2026 | BVS Bioventus Inc. | MOption exercise Restricted Stock Unitsderivative | -93,750 | $0.00 | $0 | 187,500 | Jan 13, 2026 |
| Jan 13, 2025 | BVS Bioventus Inc. | SOpen-market sale Class A Common Stock10b5-1 | -28,786 | $9.10 | $262k | 64,964 | Jan 14, 2025 |
| Jan 10, 2025 | BVS Bioventus Inc. | MOption exercise Class A Common Stock | +93,750 | $0.00 | $0 | 93,750 | Jan 13, 2025 |
| Jan 10, 2025 | BVS Bioventus Inc. | MOption exercise Restricted Stock Unitsderivative | -93,750 | $0.00 | $0 | 281,250 | Jan 13, 2025 |
Questions about Robert E Claypoole
Answered from the filings on this page, as of the latest one.
Is Robert E Claypoole buying or selling?
Not in the last 12 months. Robert E Claypoole's latest open-market trade on SEC Form 4 was sold $262k of BVS on Jan 13, 2025.
How did Robert E Claypoole's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Robert E Claypoole has 0.
Where does Robert E Claypoole file Form 4?
Robert E Claypoole has filed Form 4 at BVS (Bioventus Inc.) as President and CEO. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.